CAS: 143-57-7; Protoveratrine A
该化合物是一种复杂的藻类,产自植物的基因变异,特别是来自诸如Veratrum相册和Veratrum viride等物种.它以其强大的药理效应而著称,主要是心血管剂.蛋白质表现出血管和低血压的特性,使其在治疗高血压方面有用.通过阻塞钠渠道和影响钙离子运动,影响肌肉收缩和血管音调.它通常以白到白的晶体粉的形式出现,在酒精中溶解,在水中略微溶解.由于其生物活动,蛋白质可产生重大的副作用,包括恶心,呕吐和心血管扰动,在使用治疗性时需要谨慎使用和监测.它的使用减少了对较现代的抗血激剂的偏好,但对于其独特行动机制的药理学研究仍然感兴趣.与许多碱类物质一样,安全性和毒性剖面是其应用中的关键考虑因素.
- 英文名称Protoveratrine A
- 中文名称原藜芦碱
- IUPAC名称[(1S,2S,6S,9S,10S,11R,12R,13S,14S,15S,16S,17R,18R,19S,22S,23S,25R)-16,17-diacetyloxy-10,12,14,23-tetrahydroxy-6,10,19-trimethyl-13-[(2R)-2-methylbutanoyl]oxy-24-oxa-4-azaheptacyclo[12.12.0.02,11.04,9.015,25.018,23.019,25]hexacosan-22-yl] (2S)-2-hydroxy-2-methylbutanoate
- 其它别名PROTOVERATRINE A; 6,7-diacetate3-((+)-2-hydroxy-2-methylbutyrate)15-((-)-2-methylbutyrate); protalba; protoveratrin; [3beta(S),4alpha,6alpha,7alpha,15alpha(R),16beta]-4,9-epoxycevane-3,4,6,7,14,15,16,20-°Ctol 6,7-diacetate 3-(2-hydroxy-2-methylbutyrate) 15-(2-methylbutyrate); PROTOVERATRINE A (RG); 4α,9-Epoxycevane-3β,4,6α,7α,14,15α,16β,20-°Ctol 6,7-diacetate 3-[(S)-2-hydroxy-2-methylbutanoate]15-[(R)-2-methylbutanoate]; Puroverine
- CAS编号143-57-7
- EINECS号:205-602-9
- FDA UNII编号:XP343X1HJU
- 分子式:C41H63NO14分子量:793.95
- 产品CID: 664568
- 产品分类有机原料 → 脂质和类脂质分子 → 类固醇和类固醇衍生物
物理性质
MSDS等安全信息
欧盟法规
C&L通报REACH预注册合成工艺路线路线简述
海关参考信息
- 2905122000-异丙醇
2905143000-叔丁醇
2905310000-1,2-乙二醇
2905320000-1,2-丙二醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-10925977-B2
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
发明人：YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.
专利号:AU-2007308022-A2
优先权日:2006-10-05
标题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
专利号:AU-2007308022-A1
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
专利号:US-2008107598-A1
优先权日:2006-10-05
标 题:Efficient Synthesis of Chelators for Nuclear Imaging and Radiotherapy: Compositions and Applications
专利号:AU-2007308022-B2
优先权日:2006-10-05
标题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
专利号:CA-2664826-C
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
合成参考文献
摘要:Journal of Agricultural and Food Chemistry., 39(1875), 1991
摘要:Annales Pharmaceutiques Francaises., 14(783), 1956 []
📝 需求与反馈
尽可能描述清楚需求与问题信息
